Premium
Review article: novel antivirals for hepatitis C—sofosbuvir/velpatasvir/voxilaprevir, glecaprevir/pibrentasvir
Author(s) -
Pearlman Brian L.,
Hinds Andrew E.
Publication year - 2018
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.14977
Subject(s) - medicine , sofosbuvir , regimen , hepatitis c , gastroenterology , protease inhibitor (pharmacology) , hepatitis c virus , adverse effect , pharmacology , viral load , ribavirin , virology , virus , antiretroviral therapy
Summary Background In 2017, the hepatitis C treatment regimens sofosbuvir/velpatasvir/voxilaprevir ( SOF / VEL / VOX ) and glecaprevir/pibrentasvir (G/P) received approval from the U.S. Food and Drug Administration. Although both SOF / VEL / VOX ( NS 5B polymerase inhibitor/ NS 5A inhibitor/ NS 3/4A protease inhibitor) and G/P ( NS 3/4A protease inhibitor/ NS 5A inhibitor) are pangenotypic regimens, they are indicated for distinct subsets of patients with hepatitis C. Aim To compare and contrast available safety and efficacy data for SOF / VEL / VOX and G/P and outline their clinical utility. Methods For each of the regimens, this review outlines the indications, safety information, and the major clinical studies in which SOF / VEL / VOX and G/P were evaluated. Results SOF / VEL / VOX is positioned as a salvage regimen for patients previously treated with NS 5A inhibitors and for genotype 1a‐ and 3‐infected patients who had failed other sofosbuvir‐containing regimens. G/P is the first pangenotypic regimen with an 8‐week duration for treatment‐naïve, non‐cirrhotic patients, and it is indicated for patients with any genotype who have advanced kidney disease, including those on dialysis. Conclusion The addition of SOF / VEL / VOX and G/P to existing hepatitis C treatment options will expand the number of patients who are eligible for and responsive to treatment, thus increasing the possibility of eliminating hepatitis C as a public health issue.